Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1631
This examiner grants 30% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18037740 | SKIN SPHEROIDS AND PROCESS OF PREPARATION AND USE THEREOF | Non-Final OA | BASF SE |
| 19272607 | PROMOTER PROXIMAL SEQUENCES AND USES THEREOF FOR RNA MANUFACTURING | Non-Final OA | Helix Nanotechnologies Inc |
| 16981800 | Detection of Interaction Between an Assay Substance and Blood or Blood Components for Immune Status Evaluation and Immune-Related Disease Detection and Diagnosis | Non-Final OA | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. |
| 17931669 | METHODS FOR THE PRODUCTION OF COMMITTED CARDIAC PROGENITOR CELLS | Final Rejection | FUJIFILM Cellular Dynamics, Inc. |
| 17996541 | GENETICALLY-MODIFIED CELL LINE FOR NK CELL ACTIVATION AND AMPLIFICATION, AND USE THEREOF | Final Rejection | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 17785145 | EVALUATION METHOD OF DIFFERENTIATION STATE OF CELLS, AND CELL CULTURE SYSTEM | Non-Final OA | HITACHI HIGH-TECH CORPORATION |
| 18884441 | Compositions and Methods for Gene Delivery to the Airways and/or Lungs | Final Rejection | Krystal Biotech, Inc. |
| 17127416 | COMPOSITIONS AND METHODS FOR GENE DELIVERY TO THE AIRWAYS AND/OR LUNGS | Non-Final OA | Krystal Biotech, Inc. |
| 18137449 | METHODS OF USING PULMONARY CELLS FOR TRANSPLANTATION AND INDUCTION OF TOLERANCE | Non-Final OA | Yeda Research and Development Co. Ltd. |
| 16969406 | CD59 FOR INHIBITING INFLAMMASOME ACTIVATION | Non-Final OA | Trustees of Tufts College |
| 17786753 | ENGINEERED CELLS FOR THERAPY | Non-Final OA | Editas Medicine, Inc. |
| 17348515 | Adeno-Associated Virus Vector Delivery for Muscular Dystrophies | Non-Final OA | SAREPTA THERAPEUTICS INC. |
| 17040661 | METHOD FOR PRODUCING NATURAL KILLER CELLS | Final Rejection | GC CELL CORPORATION |
| 17438317 | CD3 RECONSTITUTION IN ENGINEERED iPSC AND IMMUNE EFFECTOR CELLS | Final Rejection | Fate Therapeutics, Inc. |
| 16765783 | USE AND PRODUCTION OF ENGINEERED IMMUNE CELLS TO DISRUPT NFAT-AP1 PATHWAY TRANSCRIPTION FACTORS | Non-Final OA | La Jolla Institute for Allergy and Immunology |
| 18066567 | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF ADENO-ASSOCIATED VIRUS | Non-Final OA | Oxford Biomedica (US) LLC |
| 16808989 | METHOD FOR PRODUCING A CELL POPULATION INCLUDING NK CELLS | Non-Final OA | GAIA BioMedicine Inc. |
| 17433221 | MONOGENIC OR POLYGENIC DISEASE MODEL ORGANISMS HUMANIZED WITH TWO OR MORE GENES | Final Rejection | NemaMetrix, Inc |
| 17639800 | NOVEL METHODS FOR REARING AND CONTROLLED RELEASE OF PREDATORY MITES | Non-Final OA | Bio-Bee SDE Eliyahu Ltd. |
| 17630856 | METHOD FOR CULTURING PRIMARY CELLS FROM SOLID TUMOR OF LUNG CANCER AND PRIMARY TUMOR CELLS FROM PLEURAL EFFUSION OF LUNG CANCER AND AUXILIARY REAGENTS | Non-Final OA | GeneX Health Co., Ltd |
| 17621687 | PREPARATION METHOD AND APPLICATION OF CTL CELL | Final Rejection | Guangzhou Anjie Biomedical Technology CO., LTD. |
| 17048702 | MEDICAL USES | Non-Final OA | XNK THERAPEUTICS AB |
| 16464030 | METHOD, DEVICE AND KIT FOR DETERMINING CARDIAC CONDUCTION | Final Rejection | Universität Rostock |
| 16085960 | CELL CULTURE MEDIUM AND CULTURE MEDIUM SUPPLEMENT | Final Rejection | Institute of Biophysics, Chinese Academy of Sciences |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy